Drug Profile

LGB 321

Alternative Names: LGB-321

Latest Information Update: 03 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Class Antineoplastics; Piperidines; Pyridines; Small molecules
Mechanism of Action PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Oct 2023 Discontinued - Preclinical for Haematological malignancies in Switzerland (unspecified route) (Novartis pipeline, October 2022)
28 Sep 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in Switzerland
03 Feb 2017 Chemical structure information added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com